An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.
Pirtobrutinib offers a heart-safer alternative to some older BTK inhibitors for treating chronic lymphocytic leukemia without loss of efficacy.
This network meta-analysis of 814 patients from 3 RCTs (ELEVATE-RR, ALPINE, BRUIN-CLL-314) provides the first indirect comparative efficacy evidence for pirtobrutinib versus second-generation covalent BTK inhibitors in BTKi-naive CLL. The findings support pirtobrutinib as an alternative to acalabrutinib/zanubrutinib with a potential cardiovascular tolerability advantage over zanubrutinib, though indirect comparison limitations apply.
What the study was
- Study design
- Bayesian network meta-analysis of RCTs
- Population
- BTKi-naive relapsed/refractory CLL patients
- Sample size
- 814
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Leukemia & Lymphoma
Why it surfaced
Fills a direct evidence gap for pirtobrutinib positioning in BTKi-naive CLL; Bayesian NMA of RCTs with common comparator. CV safety signal over zanubrutinib is clinically actionable for patient selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.